Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
ASCL1
NeuroD1
POU2F3
concordance
small cell carcinoma
spatiotemporal heterogeneity
subtype
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
27
07
2023
received:
18
05
2023
accepted:
10
08
2023
medline:
7
11
2023
pubmed:
30
8
2023
entrez:
30
8
2023
Statut:
ppublish
Résumé
Small cell lung carcinoma (SCLC) can be classified into transcription factor-based subtypes (ASCL1, NeuroD1, POU2F3). While in-vitro studies suggest intratumoral heterogeneity in the expression of these markers, how SCLC subtypes vary over time and among locations in patients remains unclear. We searched a consecutive series of patients at our institution in 2006-22 for those with greater than one available formalin-fixed paraffin-embedded SCLC sample in multiple sites and/or time-points. Immunohistochemistry for ASCL1, NeuroD1 and POU2F3 was performed and evaluated using H-scores, with subtype assigned based on the positive marker (H-score threshold >10) with the highest H-score. The 179 samples (75, lung; 51, lymph nodes; 53, non-nodal metastases) from 84 patients (74 with two, 10 with more than two samples) included 98 (54.7%) ASCL1-dominant, 47 (26.3%) NeuroD1-dominant, 15 (8.4%) POU2F3-dominant, 17 (9.5%) triple-negative and two (1.1%) ASCL1/NeuroD1 co-dominant samples. NeuroD1-dominant subtype was enriched in non-lung locations. Subtype concordance from pairwise comparison was 71.4% overall and 89.7% after accounting for ASCL1/NeuroD1-dual expressors and technical factors including <500 cells/slide, H-score thresholds and sample decalcification. No significant difference in subtype concordance was noted with a longer time lapse or with extrathoracic versus intrathoracic samples in this cohort. After accounting for technical factors, transcription factor-based subtyping was discordant among multiple SCLC samples in ~10% of patients, regardless of sample locations and time lapse. Our findings highlighted the spatiotemporal heterogeneity of SCLC in clinical samples and potential challenges, including technical and biological factors, that might limit concordance in SCLC transcription factor-based subtyping.
Substances chimiques
Transcription Factors
0
ASCL1 protein, human
0
Basic Helix-Loop-Helix Transcription Factors
0
POU2F3 protein, human
0
Octamer Transcription Factors
0
NEUROD1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
912-924Subventions
Organisme : NIH HHS
ID : R01 CA240317
Pays : United States
Organisme : NIH HHS
ID : R01 CA240317
Pays : United States
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Beasley MB, Brambilla E, MacMahon H et al. Small cell lung carcinoma. In WHO classification of tumors series, thoracic tumors. Vol. 5. 5th ed. Lyon, France: International Agency for Research on Cancer, 2021; 139-143.
Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006; 24; 4539-4544.
Varghese AM, Zakowski MF, Yu HA et al. Small-cell lung cancers in patients who never smoked cigarettes. J. Thorac. Oncol. 2014; 9; 892-896.
Lee JK, Lee J, Kim S et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J. Clin. Oncol. 2017; 35; 3065-3074.
Marcoux N, Gettinger SN, O'Kane G et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J. Clin. Oncol. 2019; 37; 278-285.
Rudin CM, Durinck S, Stawiski EW et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 2012; 44; 1111-1116.
George J, Lim JS, Jang SJ et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524; 47-53.
Rudin CM, Poirier JT, Byers LA et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer 2019; 19; 289-297.
Baine MK, Hsieh MS, Lai WV et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J. Thorac. Oncol. 2020; 15; 1823-1835.
Gay CM, Stewart CA, Park EM et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021; 39; 346-360.e7.
Hwang S, Hong TH, Park S et al. Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. Transl. Lung Cancer Res. 2021; 10; 4209-4220.
Baine MK, Febres-Aldana CA, Chang JC et al. POU2F3 in SCLC: clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC. J. Thorac. Oncol. 2022; 17; 1109-1121.
Megyesfalvi Z, Barany N, Lantos A et al. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. J. Pathol. 2022; 257; 674-686.
Qu S, Fetsch P, Thomas A et al. Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers. J. Thorac. Oncol. 2022; 17; 141-153.
Ding XL, Su YG, Yu L et al. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC). World J. Surg. Oncol. 2022; 20; 54.
Handa T, Hayashi T, Ura A et al. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. Histopathology 2023; 82; 860-869.
Hwang S, Hong TH, Kim HK et al. Whole-section landscape analysis of molecular subtypes in curatively resected small cell lung cancer: clinicopathologic features and prognostic significance. Mod. Pathol. 2023; 36; 100184.
Poirier JT, George J, Owonikoko TK et al. New approaches to SCLC therapy: from the laboratory to the clinic. J. Thorac. Oncol. 2020; 15; 520-540.
Sutherland KD, Ireland AS, Oliver TG. Killing SCLC: insights into how to target a shapeshifting tumor. Genes Dev. 2022; 36; 241-258.
Ireland AS, Micinski AM, Kastner DW et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell 2020; 38; 60-78.e12.
Paliwal A, Faust K, Alshoumer A, Diamandis P. Standardizing analysis of intra-tumoral heterogeneity with computational pathology. Genes Chromosomes Cancer 2023; 62; 526-539.
Huang YH, Klingbeil O, He XY et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 2018; 32; 915-928.